PRODUCT INFORMATION

SNDX-5613

Item No. 40758



CAS Registry No.:	2169919-21-3
Formal Name:	N-ethyl-2-[[4-[7-[[trans-4-[(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-N-(1-methylethyl)-benzamide
Synonym:	Revumenib
MF:	$C_{32}H_{47}FN_6O_4S$
FW:	630.8
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SNDX-5613 is supplied as a solid. A stock solution may be made by dissolving the SNDX-5613 in the solvent of choice, which should be purged with an inert gas. SNDX-5613 is soluble (≥10 mg/ml) in ethanol and DMSO.

Description

SNDX-5613 is a derivative of VTP-50469 (Item No. 40759), an inhibitor of the protein-protein interaction between menin and mixed-lineage leukemia 1 (MLL1), also known as lysine methyltransferase 2A (KMT2A). It inhibits the growth of patient-derived acute myeloid leukemia (AML) cells expressing the gene encoding upstream binding factor (UBF) and containing tandem duplications (UBF-TDs) when UBF-TD-containing AML cells are co-cultured with mesenchymal stem cells.[1] SNDX-5613 (50 mg/kg) reduces disease burden and improves survival when used alone and, to a greater extent, when used in combination with the CBP and p300 inhibitor GNE-781 (Item No. 36450) in a MOLM-13 mouse xenograft model.[2] It also reduces disease burden and increases survival in patient-derived xenograft (PDX) mouse models in which tumor cells contain rearrangements in the gene encoding KMT2A or mutations in the gene encoding nucleophosmin 1 (NPM1).[3]

References

1. Barajas, J.M., Rasouli, M., Umeda, M., *et al*. Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors. *Blood* **143(7)**, 619-630 (2024).
2. Fiskus, W., Mill, C.P., Birdwell, C., *et al.* Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. *Blood Cancer J.* **13(1)**, 53 (2023).
3. Issa, G.C., Aldoss, I., Dipersio, J., *et al.* The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. *Nature* **615(7954)**, 920-924 (2023).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM